Medtide Inc.

Based in China, Medtide Inc. is a peptide-focused company specializing in contract research, development, and manufacturing services tailored for the pharmaceutical and life sciences sectors. Founded in 2020 in Hangzhou, China, Medtide Inc. provides peptide-based drug solutions through an integrated CRDMO model.

The company has completed a total of 4 deals, with its latest funding round being a Pre-IPO round in which it raised USD 10. 00 mn from investors including Dragon Merit Holdings Limited and Welight Capital. Medtide Inc. specializes in contract research, development, and manufacturing services (CRDMO) with a focus on peptide-based drug solutions.

The company offers end-to-end services that encompass early discovery, preclinical research, clinical development, and commercial production, effectively addressing the needs of clients in the pharmaceutical and life sciences sectors. With a client base exceeding 1,000 customers across over 50 countries, Medtide aims to facilitate the market introduction of innovative therapeutics that significantly impact human health. The key markets served include regions in Asia, North America, and Europe, where the company provides tailored solutions for peptide and oligonucleotide drug development to support the diverse needs of its pharmaceutical partners. The revenue model of Medtide Inc.

is structured around B2B transactions, focusing on partnerships with pharmaceutical companies that require extensive research and development capabilities. The firm engages clients through contractual agreements, which may incorporate various pricing strategies based on project scope and complexity. These agreements typically entail milestones tied to specific deliverables, including research phases, regulatory submissions, and commercial-scale production. The flagship offerings, such as its peptide CRDMO platform, are integral to revenue generation, ensuring the company maintains a steady inflow from its extensive service portfolio while catering to the evolving demands of its international client base.

In June 2025, Medtide Inc. plans to raise HKD 514. 08 million through an IPO, issuing 16. 8 million shares at HKD 30.

6 per share on the Hong Kong Exchanges and Clearing Ltd under the ticker symbol '3880'. This funding will be utilized to support the launch of new peptide-based products and expand operations into new markets, including increased outreach in Asia and North America, aiming for significant market penetration by 2026.